共 50 条
- [25] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
- [28] Advances on immune-related adverse events associated with immune checkpoint inhibitors Frontiers of Medicine, 2021, 15 : 33 - 42